PRRT2 and cancer: Ro‐31‐8220 is a synthetic bisindolylmaleimide derivative and pan‐protein kinase C (PKC) inhibitor that selectively targets the ATP‐binding site of PKC isoforms, demonstrating anti‐proliferative effects in preclinical cancer models.